Form 4: Marimed Director Eva Selhub Receives RSU Grant

Marimed Inc. director Eva Selhub M.D. was granted 166,985 Restricted Stock Units as compensation for her board service, vesting fully on December 15, 2025.

Summary

• Dr. Eva Selhub, a director of Marimed Inc. (MRMD), reported changes in her beneficial ownership.
• She was granted 166,985 Restricted Stock Units (RSUs) on December 5, 2025.
• These RSUs convert to common stock on a one-for-one basis and are scheduled to vest in full on December 15, 2025.
• The RSUs were granted in lieu of cash payment for a portion of her fees for serving on the Issuer's Board of Directors.
• Following this transaction, Dr. Selhub beneficially owns 315,686 shares of common stock and 166,985 RSUs directly.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of director equity compensation, which is a common practice to align management and shareholder interests. It does not contain significant positive or negative news regarding company performance or strategy.

Positives

• Director compensation through equity (RSUs) aligns the director's interests with those of shareholders, promoting long-term value creation.
• The grant of RSUs in lieu of cash suggests a commitment to the company's long-term performance by the director and conserves company cash.

Future Outlook

No forward-looking statements or guidance are provided beyond the vesting date of the RSUs.

Industry Context

Equity compensation, such as Restricted Stock Units, is a common practice across various industries, including the cannabis sector where Marimed operates, to incentivize directors and executives and align their interests with shareholders. This particular filing reflects a standard compensation method for board service.

Comparison to Industry Standards

• Equity-based compensation for directors is a standard practice in publicly traded companies across industries.
• While specific grant sizes vary by company size, industry, and individual contribution, the use of RSUs to compensate board members is a widely accepted corporate governance practice.

Corporate Governance

Related Party Transactions

• Grant of 166,985 Restricted Stock Units to Dr. Eva Selhub, a director, as compensation for her board service, in lieu of cash.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's interests with shareholders, potentially fostering long-term value creation and conserving company cash.
• Director (Eva Selhub): Receives equity compensation, which ties her financial interest directly to the company's stock performance.

Next Steps

• The 166,985 Restricted Stock Units are scheduled to vest in full on December 15, 2025.

Key Dates

Recommendation

This Form 4 filing is a routine disclosure of director compensation through equity, which is a standard practice to align interests. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions, as this specific filing is not a catalyst for a buy or sell decision.

Keywords

Marimed Inc., MRMD, Form 4, SEC filing, Restricted Stock Units, RSU grant, Director compensation, Beneficial ownership, Insider transaction, Equity compensation